Genentech Inc.'s most advanced immunotherapy candidate, atezolizumab, met its primary endpoint in a pivotal phase II study, shrinking tumors in people with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose disease expressed programmed cell death ligand-1 (PD-L1), and setting the stage for an early 2016 registration filing.